First Manhattan
IOVA icon

First Manhattan’s Iovance Biotherapeutics IOVA Stock Holding History

First Manhattan’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$102K Hold
28,998
– – ﹤0.01% 741
2025
Q4 		$79.2K Sell
28,998
-25,302
-47% -$58.5K ﹤0.01% 720
2025
Q3 		$118K Buy
+54,300
New +$128K ﹤0.01% 700
2024
Q2 		– Sell
-550
Closed -$8.15K – 978
2024
Q1 		$8.15K Buy
+550
New +$6.4K ﹤0.01% 1134

Other funds holding IOVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MFM
MHR Fund Management New York $1.37B AUM 68.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ICM
Invenomic Capital Management Boston, Massachusetts $2.18B AUM 0.03% 1-Year Est. Return

First Manhattan's IOVA Position: Q1 2026 in Review

First Manhattan held its Iovance Biotherapeutics (IOVA) position steady in Q1 2026 at 28,998 shares worth $102K. The position accounts for ﹤0.01% of the portfolio, ranked #741.

First Manhattan first reported a position in IOVA in Q1 2024 and has held it in 4 quarters since. The position peaked at $118K in Q3 2025. 285 funds tracked by Wall St. Rank hold IOVA as of Q1 2026.

  • First Manhattan held 28,998 shares of Iovance Biotherapeutics worth $102K as of Q1 2026.
  • First Manhattan left its Iovance Biotherapeutics share count unchanged in Q1 2026.
  • Iovance Biotherapeutics made up ﹤0.01% of First Manhattan's portfolio in Q1 2026, its #741 holding.
  • First Manhattan first reported a position in Iovance Biotherapeutics in Q1 2024 and has held it in 4 quarters since.
  • First Manhattan's Iovance Biotherapeutics position peaked at $118K in Q3 2025.
  • 285 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q1 2026.

Based on First Manhattan's 13F filing for Q1 2026, filed 15 May 2026.